title: Potential anti-inflammatory effects of maraviroc in HIV-positive patients: a pilot study of inflammation, endothelial dysfunction, and coagulation markers.
abstract: Persistent immune activation and chronic inflammation significantly contribute to non-AIDS morbidity in HIV-infected patients. The HIV inhibitor maraviroc (MVC) targets the cellular chemokine CCR5 HIV co-receptor, which is involved in important inflammatory pathways. MVC could have significant anti-inflammatory and anti-atherosclerotic effects, also reducing immune activation. We designed a pilot study to determine which plasma biomarkers of inflammation, endothelial dysfunction, and hypercoagulability were modified by MVC in 2 groups of 10 patients starting MVC-free or MVC-containing regimens. Ten age- and gender-matched healthy controls were also included. We found higher levels of all inflammatory biomarkers in HIV-infected patients compared to healthy controls. Both groups showed decreasing levels of interleukin (IL)-17, IL-10, and macrophage inflammatory protein (MIP)-1a following the achievement of viral suppression. Vascular cell adhesion molecule (VCAM)-1 levels were decreased in the MVC group and increased in the MVC-free group. In conclusion, some inflammatory biomarkers tend to decrease with the salvage regimen; MVC was not associated with a better impact on these measured markers.
authors.affiliation: From the 1 Division of Infectious Diseases, University of Perugia , Perugia.
authors.forename: Daniela
authors.initials: D
authors.lastname: Francisci
authors.forename: Emanuela
authors.initials: E
authors.lastname: Falcinelli
authors.forename: Silvia
authors.initials: S
authors.lastname: Baroncelli
authors.forename: Eleonora
authors.initials: E
authors.lastname: Petito
authors.forename: Enisia
authors.initials: E
authors.lastname: Cecchini
authors.forename: Liliana Elena
authors.initials: LE
authors.lastname: Weimer
authors.forename: Marco
authors.initials: M
authors.lastname: Floridia
authors.forename: Paolo
authors.initials: P
authors.lastname: Gresele
authors.forename: Franco
authors.initials: F
authors.lastname: Baldelli
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D015415:Biomarkers / Q000097:blood; D065100:CCR5 Receptor Antagonists / Q000008:administration & dosage*; D016022:Case-Control Studies; D003510:Cyclohexanes / Q000008:administration & dosage*; D016207:Cytokines / Q000097:blood*; D005260:Female; D023581:HIV Fusion Inhibitors / Q000008:administration & dosage; D015658:HIV Infections / Q000097:blood* / Q000188:drug therapy*; D006801:Humans; D007249:Inflammation / Q000097:blood / Q000188:drug therapy / Q000821:virology; D008297:Male; D000077592:Maraviroc; D008875:Middle Aged; D010865:Pilot Projects; D019851:Thrombophilia / Q000097:blood / Q000821:virology; D014230:Triazoles / Q000008:administration & dosage*
chemical_list: D000893:Anti-Inflammatory Agents; D015415:Biomarkers; D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D016207:Cytokines; D023581:HIV Fusion Inhibitors; D014230:Triazoles; D000077592:Maraviroc
keywords: HIV infection; cytokines; inflammation; maraviroc